<DOC>
	<DOCNO>NCT02714608</DOCNO>
	<brief_summary>Ginsenoside H drip pill kind traditional Chinese medicine ( TCM ) , This study conduct evaluate efficacy safety ginsenoside H drip pill patient advance ( stage ⅢB/Ⅳ ) Non-small Cell Lung Cancer ( Syndrome Of Qi-Deficiency ) explore optimal dosage</brief_summary>
	<brief_title>A Study Ginsenoside H Dripping Pills Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Pathologically cytologically proven stage IIIB/IV NSCLC measurable lesion ( include postoperative recurrence metastasis ) 2 . The patient treat surgical resection , conventional radiotherapy chemotherapy molecular target drug treatment failure , willing accept , intolerance radiotherapy chemotherapy molecular target therapy . 3 . The TCM Syndrome diagnosis QiDeficiency . 4 . Aged 1875 year , male female . 5 . ECOG performance status 02 . 6 . Expected survive 3 month . 7 . Joined test voluntarily sign Informed consent GCP regulation . 1 . Liver kidney damage ( TBIL、ALT、AST high limit normal value 1.5 time , abnormal Cr ) . 2 . Patients significant cachexia . 3 . Untreated symptomatic brain metastasis . 4 .Allergic constitution , variety drug allergy . 5 .Combined severe cardiovascular , hepatic , renal disease , pregnancy breastfeed woman , psychopath . 6 . Participated clinical trial within 3 month . 7 . Treated chemotherapy , radiotherapy target therapy within 4 week . 8 . Possible treated chemotherapy , radiotherapy target therapy study . 9 . Not fit clinical trial judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>